Hovione signs Captisol technology co-promotion agreement with Ligand

Under the agreement, Hovione will leverage Captisol technology in solubilization programs such as amorphous solid dispersions, crystal design and size reduction and control of particle size.

Hovione particle design vice president Dr. Colin Minchom said, "There is no single solution to improving bioavailability and for a customer to access diverse options with a single supplier provides for greater probability of success and speedier outcomes."

Captisol, a chemically modified cyclodextrin, is designed to optimize drug solubility and stability and is used in six marketed products at present.

Ligand executive vice president and chief operating officer Mathew Foehr said, "Providing for greater access to Captisol should efficiently enable the successful development of more poorly soluble molecules and further increase our Captisol partnership portfolio."